背景:药用植物的植物化学研究正在迅速普及,具有许多药理作用。本研究旨在确定由五种药用植物组成的ClearbresiblePlus提取物(CBL-P)的抗氧化能力以及抗癌和抗迁移活性,高良姜,PiperNigrum,金叶柑橘,Tiliacoratriandra,和大麻对人结肠癌细胞SW620和HCT116细胞系,和人非小细胞肺癌细胞A549和NCI-H460细胞系。
方法:在本研究中,使用90%乙醇提取干燥植物粉末。此外,通过DPPH和ABTS测定法研究CBL-P的抗氧化活性,并使用Griess反应使用一氧化氮测定法研究抗炎活性。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基-2H-四唑溴化物(MTT)和划痕测定法研究了CBL-P的抗增殖和抗迁移。
结果:结果显示,对于所有四种细胞系,CBL-P具有有效的抗增殖活性,IC50值呈浓度和时间依赖性。CBL-P还对所有研究的癌细胞具有有效的抗迁移活性。CBL-P在孵育48小时后对四种不同类型的癌细胞(A549,NCI-H460,HCT116和SW620)具有抗迁移活性,在A549细胞(伤口闭合的10.23%)和NCI-H460细胞(伤口闭合的9.16%)中,在最高测试浓度(15μg/mL)下观察到最大的效果。CBL-P还有效减少HCT116和SW620细胞的迁移,闭合面积范围为10-50%。此外,CBL-P具有抗氧化活性,DPPH和ABTS测定的IC50值分别为8.549±0.241mg/mL和2.673±0.437mg/mL。分别。CBL-P在40μg/mL的浓度下也显示出抗炎活性,对NO产生具有最佳抑制活性。
结论:结论:混合物提取物具有抗氧化和抗炎活性。此外,混合植物提取物对SW620,HCT116,A549和NCI-H460细胞显着表现出抗增殖和抗迁移活性(P≤0.05)。一起来看,我们的研究结果表明,药用植物可能具有协同作用,当用作佐剂时,可能会增强癌症治疗的有效性.这些发现为今后努力探索作用机制提供了坚实的科学基础。
BACKGROUND: The phytochemical study of medicinal plants is rapidly gaining popularity with many pharmacologic effects. This study aims to determine the antioxidant capacity as well as anticancer and antimigration activities of Clear belongs Plus extract (CBL-P) which consisted of five medicinal plants namely, Alpinia galanga, Piper nigrum, Citrus aurantifolia, Tiliacora triandra, and Cannabis sativa on human colon cancer cells SW620 and HCT116 cell lines, and human non-small cell lung cancer cells A549 and NCI-H460 cell lines.
METHODS: In this study the dried-plant powder was extracted using 90% ethanol. Additionally, CBL-P was studied antioxidative activity via DPPH and ABTS assays and anti-inflammatory activities using nitric oxide assay using Griess reaction. Antiproliferation and antimigration of CBL-P were investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and scratch assay.
RESULTS: The results showed that CBL-P had potent antiproliferative activity with IC50 values in a concentration- and time-dependent manners for all four cell lines. CBL-P also possessed potent antimigration activity against all studied cancer cells. CBL-P demonstrated antimigration activity on four different types of cancer cells (A549, NCI-H460, HCT116, and SW620) after 48 h of incubation, with the greatest effect seen at the highest concentration tested (15 μg/mL) in A549 cells (10.23% of wound closure) and NCI-H460 cells (9.16% of wound closure). CBL-P was also effective in reducing migration in HCT116 and SW620 cells, with a range of closure area from 10-50%. In addition, CBL-P had antioxidant activity with IC50 values of 8.549 ± 0.241 mg/mL and 2.673 ± 0.437 mg/mL for DPPH and ABTS assays, respectively. CBL-P also showed anti-inflammatory activity with the best inhibitory activity on NO production at a concentration of 40 μg/mL.
CONCLUSIONS: In conclusion, the mixture extract possessed antioxidant and anti-inflammatory activity. Furthermore, the mixture plant extract significantly exhibited antiproliferative and antimigration activities on SW620, HCT116, A549, and NCI-H460 cells (P ≤ 0.05). Taken together, our results suggest that medicinal plants may have synergistic effects that could potentially enhance the effectiveness of cancer treatment when used as adjuvants. These findings provide a solid scientific foundation for future efforts to explore the mechanism of action.